Notes to Accounts of Medicamen Biotech Ltd.

Mar 31, 2025

2.13 Provisions

Provisions are recognized when the Company has a
present obligation (legal or constructive) as a result of
a past event, it is probable that an outflow of resources
embodying economic benefits will be required to settle
the obligation and a reliable estimate can be made of the
amount of the obligation. When the Company expects
some or all of a provision to be reimbursed, for example,
under an insurance contract, the reimbursement is
recognized as a separate asset, but only when the
reimbursement is virtually certain. The expense relating
to a provision is presented in the Statement of Profit
and Loss net of any reimbursement.

If the effect of the time value of money is material,
provisions are discounted using a current pre-tax rate
that reflects, when appropriate, the risks specific to the
liability. When discounting is used, the increase in the
provision due to the passage of time is recognized as a
finance cost.

2.14 Retirement and other employee benefits
Short-term obligations

Liabilities for wages and salaries, including non¬
monetary benefits that are expected to be settled
wholly within 12 months after the end of the period
in which the employees render the related service are
recognized in respect of employees’ services up to
the end of the reporting period and are measured at
the amounts expected to be paid when the liabilities
are settled. The liabilities are presented as current
employee benefit obligations in the balance sheet.

Other long-term employee benefit obligations

The liabilities for earned leave and sick leave are not
expected to be settled wholly within 12 months after
the end of the period in which the employees render
the related service. They are therefore measured as
the present value of expected future payments to be
made in respect of services provided by employees up
to the end of the reporting period using the projected
unit credit method. The benefits are discounted using
the market yields at the end of the reporting period that
have terms approximating to the terms of the related
obligation.

The obligations are presented as current liabilities
in the balance sheet if the entity does not have an
unconditional right to defer settlement for at least
twelve months after the reporting period, regardless of
when the actual settlement is expected to occur.

Post-employment obligations

The company operates the following post-employment
scheme:

(a) defined benefit plans such as gratuity; and

(b) defined contribution plans such as provident fund.
Bonus plans

The company recognizes liability and an expense for
bonuses. The company recognizes a provision where
contractually obliged or where there is a past practice
that has created a constructive obligation.

2.15 Investments in subsidiaries

Medicamen has forayed into the domestic market 1st
times through its newly formed subsidiary namely
Medicamen Life Sciences Private Limited with a vision
to have presence in every region of the country in next
two years to become most admired Pharma Company
in segment of Cardio-Vascular, Diabetics and other
related therapy.

In respect of equity investments, the entity prepares
separate financial statements and account for its
investments in subsidiary at cost, net of impairment if
any.

2.16 Cash and Cash Equivalents

Cash and Cash equivalents in the balance sheet
comprise cash at banks and on hand and short-term
deposits with an original maturity of three months
or less, which are subject to an insignificant risk of
changes in value.

For the purpose of the statement of cash flows, cash
and cash equivalents consist of cash and short-term
deposits, as defined above, net of outstanding bank
overdrafts as they are considered an integral part of the
Group’s cash management.

2.17 Trade Receivables

Trade receivables are recognized initially at fair value
and subsequently measured at amortized cost using
the effective interest method, less provision for
impairment.

2.18 Trade and Other Payables

These amounts represent liabilities for goods and
services provided to the company prior to the end of
the financial year which are unpaid. The amounts
are unsecured and are usually paid within 30 days of
recognition. Trade and other payables are presented as

current liabilities unless payment is not due within 12
months after the reporting period. They are recognized
initially at their fair value and subsequently measured
at amortized cost using the effective interest method.

2.19 Contributed Equity

Equity shares are classified as equity.

2.20 Earnings Per Share

Basic earnings per share

Basic earnings per share is calculated by dividing:

• the profit attributable to owners of the company

• by the weighted average number of equity shares
outstanding during the financial year, adjusted for
bonus elements in equity shares issued during the
year and excluding treasury shares.

2.21 Contingent Liabilities

In the opinion of the Board of Directors, adequate
provisions have been made in the accounts for all
known liabilities. The value of current assets, loans and
advances have a value on realization in the ordinary
course of business at least equal to the amount at
which they are stated in the balance sheet, unless
otherwise stated.

The company does have any pending litigation which
would impact on its financial position.

2.22 New standards and interpretations not yet adopted

Ministry of Corporate Affairs ("MCA") notifies new
standard or amendments to the existing standards
under Companies (Indian Accounting Standards)
Rules as issued from time to time. On March 23, 2022,
MCA amended the Companies (Indian Accounting
Standards) Amendment Rules, 2022, applicable from
April 01,2022, as below:

Ind AS 103 - Reference to Conceptual Framework

The amendments specify that to qualify for recognition
as part of applying the acquisition method, the
identifiable assets acquired, and liabilities assumed
must meet the definitions of assets and liabilities in the
Conceptual Framework for Financial Reporting under
Indian Accounting Standards (Conceptual Framework)
issued by the Institute of Chartered Accountants of
India at the acquisition date. These changes do not
significantly change the requirements of Ind AS 103.
The Company does not expect the amendment to have
any significant impact in its financial statements.

2.23 Key Financial Ratios:

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Company is required
to give details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year)
in key financial ratios

Ind AS 16 - Proceeds before intended use

The amendments mainly prohibit an entity from
deducting from the cost of property, plant and
equipment amounts received from selling items
produced while the company is preparing the asset for
its intended use. Instead, an entity will recognize such
sales proceeds and related cost in profit or loss. The
Company does not expect the amendments to have
any impact in its recognition of its property, plant and
equipment in its financial statements.

Ind AS 37 - Onerous Contracts - Costs of Fulfilling a
Contract

The amendments specify that the "cost of fulfilling" a
contract comprises the "costs that relate directly to the
contract". Costs that relate directly to a contract can
either be incremental costs of fulfilling that contract
(examples would be direct labor, materials) or an
allocation of other costs that relate directly to fulfilling

contracts. The amendment is essentially a clarification
and the Company does not expect the amendment to
have any significant impact in its financial statements.

Ind AS 109 - Annual Improvements to Ind AS (2021)

The amendment clarifies which fees an entity includes
when it applies the "10 percent" test of Ind AS 109 in
assessing whether to derecognize a financial liability.
The Company does not expect the amendment to have
any significant impact in its financial statements.

Ind AS 116 - Annual Improvements to Ind AS (2021)

The amendments remove the illustration of the
reimbursement of leasehold improvements by the
lessor in order to resolve any potential confusion
regarding the treatment of lease incentives that might
arise because of how lease incentives were described
in that illustration. The Company does not expect
the amendment to have any significant impact in its
financial statements.

As per our report of even date attached

For Rai Qimat & Associates For and on behalf of the Board

Chartered Accountants Medicamen Biotech Limited

Firm Regn. No. 013152C

CA Qimat Rai Garg Parul Choudhary Chandan Kumar Ashwani Kumar Sharma Rahul Bishnoi

Partner Company Secretary Chief Financial Officer Director Chairman

M.No.: 080857 (ACS : 44157) (PAN: AKBPK1234B) (DIN: 00325634) (DIN: 00317960)

UDIN: 25080857BMLCPJ8565

Place: Gurugram
Date: May 30, 2025

---

Mar 31, 2024

CORPORATE INFORMATION

The Company is a public company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on two recognized stock exchanges in India. The registered office of the Company is located at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019. The Company is engaged in manufacturing of Finished Dosage Forms (FDF) and its manufacturing facilities are situated at:

1	Finished Dosage Forms (FDF)	: SP-1192, A & B Phase-IV, Industrial Area, Distt Alwar, Bhiwadi-301019 (Rajasthan)
2	Finished Dosage Forms (FDF)	: Plot No 86 & 87, Sector 6A, IIE, Sidcul, Bhel, Ranipur, Haridwar-249403 (Uttrakhand)
3	Oncology formulation	: Plot No 84 & 85, Sector 6A, IIE, Sidcul, Bhel, Ranipur, Haridwar-249403 (Uttrakhand)
4	R&D Facility	: SP-1192, A & B Phase-IV, Industrial Area, Distt Alwar, Bhiwadi-301019 (Rajasthan)

SIGNIFICANT ACCOUNTING POLICIES2.1 Basis of preparation

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards (''Ind AS’), under the historical cost basis except for certain financial instruments which are measured at fair values at the end of each reporting period as explained in the accounting policies below, the provisions of the Companies Act, 2013 (''the Act’) (to the extent notified) and guidelines issued by Securities and Exchange Board of India (SEBI). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules issued thereafter.

2.2 Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/non-current classification. An asset is treated as current when it is:

• Expected to be realized or intended to be sold or consumed in normal operating cycle

• Held primarily for the purpose of trading

• Expected to be realized within twelve months after the reporting period, or

• Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

• I t is expected to be settled in normal operating cycle

• It is held primarily for the purpose of trading

• It is due to be settled within twelve months after the reporting period, or

• There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as noncurrent.

Deferred tax assets and liabilities are classified as noncurrent assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

2.3 Foreign currencies

The financial statements are presented in Indian rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the Company operates.

Transactions in foreign currencies are initially recorded by the Company at its functional currency spot rates at the date the transaction first qualifies for recognition. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Exchange differences arising on settlement or translation of monetary items are recognized in Statement of Profit and Loss.

2.4 Fair value measurement

The Company measures financial instruments, such as derivatives, at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

• In the principal market for the asset or liability, or

• In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant''s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

• Level 1: Quoted (unadjusted) market prices in active markets for identical assets or liabilities

• Level 2: Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

• Level 3: Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The Company determines the appropriate valuation techniques and inputs for fair value measurements. In estimating the fair value of an asset or a liability, the Company uses market-observable data to the extent it is available. Where level 1 inputs are not available, the Company engages third party qualified valuers to perform the valuation. Any change in the fair value of each asset and liability is also compared with relevant external sources to determine whether the change is reasonable.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

2.5 Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade

discounts and volume rebates after taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government. The Company derives revenues primarily from manufacture and export of Pharmaceuticals products.

2.6 Dividends

Revenue is recognized when the Company''s right to receive the payment is established, which is generally when shareholders approve the dividend.

Final Dividend on shares is recorded as a liability on the date of approval by the shareholders and interim dividends are recorded as a liability on the date of declaration by the Company''s Board of Directors. The entity recognized the income tax consequences of dividends in profit or loss, other comprehensive income or equity according to where the entity originally recognized those past transactions or events. The Finance Act, 2020 has repealed the Dividend Distribution Tax (DDT). The Company is now required to pay/distribute dividend after deducting applicable taxes. The remittance of dividends outside India is governed by Indian law on foreign exchange and is also subject to withholding tax at applicable rates.

2.7 Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date in the countries where the Company operates and generates taxable income. Current income tax relating to items recognized outside profit or loss is recognized outside profit or loss (either in other comprehensive income ("OCI") or in equity). Current tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity.

Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provision where appropriate.

2.8 Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognized for all taxable temporary differences.

Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which

the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognized outside profit or loss is recognized outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

2.9 Property, plant and equipment Capital work-in-progress, property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied.

All other expenses on existing property, plant and equipment, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred.

Subsequent expenditure related to an item of property, plant and equipment is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance or extends its estimated useful life.

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows:

1. Factory Buildings : 30 Years

2. Lease Hold Land : 99 Years

3. Plant Equipment : 5 to 20 Years

4. Furniture and Fixtures : 10 Years

5. Vehicles : 3 to 10 Years

6. Computers : 3 to 6 Years

An item of property, plant and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising from derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss when the asset is derecognized.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

2.10 Intangible assets

Costs relating to software, which is acquired, are capitalized and amortized on a straight-line basis over their estimated useful lives of 5 to 10 Years.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit or loss when the asset is derecognized.

Amortization method, useful lives and residual values are reviewed at the end of each financial year and adjusted if appropriate.

2.11 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

2.12 Inventories

Inventories are valued at the lower of cost and net realizable value. Costs incurred in bringing each product to its present location and conditions are accounted for as follows:

Raw materials: Materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition.

Finished goods and work-in-progress: cost includes cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity.

Stores, spares and packing materials: are valued at the lower of cost and net realizable value, net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

2.13 Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the Statement of Profit and Loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

2.14 Retirement and other employee benefits Short-term obligations

Liabilities for wages and salaries, including nonmonetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

Other long-term employee benefit obligations

The liabilities for earned leave and sick leave are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. They are therefore measured as

the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. The benefits are discounted using the market yields at the end of the reporting period that have terms approximating to the terms of the related obligation.

The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur.

Post-employment obligations

The Company operates the following post-employment scheme:

(a) defined benefit plans such as gratuity; and

(b) defined contribution plans such as provident fund. Bonus plans

The Company recognizes liability and an expense for bonuses. The Company recognizes a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

2.15 Investments in subsidiaries

Medicamen has forayed into the domestic market 1st times through its newly formed subsidiary namely Medicamen Life Science Private Limited with a vision to have presence in every region of the country in next two years to become most admired pharma company in segment of cardio vascular, diabetics and other related therapy.

In respect of equity investments, the entity prepares separate financial statements and account for its investments in subsidiary at cost, net of impairment if any.

2.16 Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Group’s cash management.

2.17 Trade receivables

Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less provision for impairment.

2.18 Trade and other payables

These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.

2.19 Contributed equity

Equity shares are classified as equity.

2.20 Earnings per share Basic earnings per share

Basic earnings per share is calculated by dividing:

• the profit attributable to owners of the Company

• by the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares issued during the year and excluding treasury shares

2.21 Contingent Liabilities

In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

2.22 New standards and interpretations not yet adopted

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On March 23, 2022, MCA amended the Companies (Indian Accounting Standards) Amendment Rules, 2022, applicable from April 01,2022, as below:

Ind AS 103 - Reference to Conceptual Framework

The amendments specify that to qualify for recognition as part of applying the acquisition method, the identifiable assets acquired, and liabilities assumed must meet the definitions of assets and liabilities in the Conceptual Framework for Financial Reporting under

Indian Accounting Standards (Conceptual Framework) issued by the Institute of Chartered Accountants of India at the acquisition date. These changes do not significantly change the requirements of Ind AS 103. The Company does not expect the amendment to have any significant impact in its financial statements.

Ind AS 16 - Proceeds before intended use

The amendments mainly prohibit an entity from deducting from the cost of property, plant and equipment amounts received from selling items produced while the Company is preparing the asset for its intended use. Instead, an entity will recognize such sales proceeds and related cost in profit or loss. The Company does not expect the amendments to have any impact in its recognition of its property, plant and equipment in its financial statements.

Ind AS 37 - Onerous Contracts - Costs of Fulfilling a Contract

The amendments specify that the "cost of fulfilling" a contract comprises the "costs that relate directly to the contract". Costs that relate directly to a contract can either be incremental costs of fulfilling that contract (examples would be direct labour, materials) or an allocation of other costs that relate directly to fulfilling contracts. The amendment is essentially a clarification and the Company does not expect the amendment to have any significant impact in its financial statements. Ind AS 109 - Annual Improvements to Ind AS (2021) The amendment clarifies which fees an entity includes when it applies the "10 percent" test of Ind AS 109 in assessing whether to derecognize a financial liability. The Company does not expect the amendment to have any significant impact in its financial statements.

Ind AS 116 - Annual Improvements to Ind AS (2021) The amendments remove the illustration of the reimbursement of leasehold improvements by the lessor in order to resolve any potential confusion regarding the treatment of lease incentives that might arise because of how lease incentives were described in that illustration. The Company does not expect the amendment to have any significant impact in its financial statements.

---

Mar 31, 2023

2.27 Contingent liabilities not provided for in respect of :			(Amount in '' Lakhs)
S No.	Particulars	2022-23	2021-22
1.	Import Letter of credit USD 5,18,250.00 (Previous Year USD 1,64,988.15 )	'' 426.21	'' 125.39
2.	Inland Letter of Credit	'' 254.61	'' 158.42
3.	Foreign Guarantee USD 1,85,011.00 (Previous Year USD 3,65,132.00 )	'' 152.34	'' 277.19
4.	Inland Guarantee	'' 23.29	'' 24.11

---

Mar 31, 2018

NOTE 1'': Corporate information:

Medicamen Biotech Limited was registered with ROC, New Delhi, under Registration No. 056594 dated 22nd December, 1993. Old registration number has been converted into new corporate identification number (CIN) L74899DL 1993PLC056594. Registered office of the Company is 1506, Chiranjiv Tower, 43, Nehru place New Delhi-110019. The Company is manufacture of Pharmaceuticals formulations products.

First-time adoption of Ind AS Transition to Ind AS

These are the Company’s first financial statements prepared in accordance with Ind AS.

The accounting policies set out have been applied in preparing the financial statements for the year ended 31st March, 2018, the comparative information presented in these financial statements for the year ended 31st March, 2017 and in the preparation of an opening Ind AS balance sheet at 1st April, 2016 (the Company’s date of transition). In preparing its opening Ind AS balance sheet, the Company has adjusted the amounts reported previously in financial statements prepared in accordance with the accounting standards notified under Companies (Accounting Standards) Rules, 2006 (as amended) and other relevant provisions of the Act (previous GAAP or Indian GAAP). An explanation of how the transition from previous GAAP to Ind AS has affected the Company’s financial position, financial performance and cash flows is set out in the following tables and notes.

A. Exemptions and exceptions availed

Set out below are the applicable Ind AS 101 optional exemptions and mandatory exceptions applied in the transition from previous GAAP to Ind AS.

A.1 Ind AS optional exemptions A.1.1 Business combinations

Ind AS 101 provides the option to apply Ind AS 103 prospectively from the transition date or from a specific date prior to the transition date. This provides relief from full retrospective application that would require restatement of all business combinations prior to the transition date.

The Company elected to apply Ind AS 103 prospectively to business combinations occurring after its transition date. Business combinations occurring prior to the transition date have not been restated. The Company has applied same exemption for investment in associates and joint ventures.

A.1.2 Deemed cost

Ind AS 101 permits a first-time adopter to elect to continue with the carrying value for all of its property, plant and equipment as recognised in the financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as its deemed cost as at the date of transition after making necessary adjustments for decommissioning liabilities. This exemption can also be used for intangible assets covered by Ind AS 38 Intangible Assets and investment property covered by Ind AS 40 Investment Properties.

Accordingly, the Company has elected to measure all of its property, plant and equipment, intangible assets and investment property at their previous GAAP carrying value.

A.1.3 Designation of previously recognised financial instruments

Ind AS 101 allows an entity to designate investments in equity instruments at FVOCI on the basis of the facts and circumstances at the date of transition to Ind AS. The Company has elected to apply this exemption for its investment in equity investments.

A.2.1 Estimates

An entity’s estimates in accordance with Ind AS at the date of transition to Ind AS shall be consistent with estimates made for the same date in accordance with previous GAAP (after adjustments to reflect any difference in accounting policies), unless there is objective evidence that those estimates were in error.

Ind AS estimates as at 1st April, 2016 are consistent with the estimates as at the same date made in conformity with previous GAAP.

A.2.2 De-recognition of financial assets and liabilities

Ind AS 101 requires a first-time adopter to apply the de-recognition provisions of Ind AS 109 prospectively for transactions occurring on or after the date of transition to Ind AS. However, Ind AS 101 allows a first-time adopter to apply the derecognition requirements in Ind AS 109 retrospectively from a date of the entity’s choosing, provided that the information needed to apply Ind AS 109 to financial assets and financial liabilities derecognised as a result of past transactions was obtained at the time of initially accounting for those transactions.

A.2.3 Classification and measurement of financial assets

Ind AS 101 requires an entity to assess classification and measurement of financial assets (investment in debt instruments) on the basis of the facts and circumstances that exist at the date of transition to Ind AS.

---

Mar 31, 2017

NOTE ''1'': Information required to be disclosed under Micro, Small and Medium Enterprises Development Act, 2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as per terms except for special reasons.

NOTE ''2'': Contingent Liabilities: In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

NOTE ''3'' Value of Imports Calculated on C.I.F. basis: Rs. 5,86,98,023

(Rs. 2,89,42,018)

NOTE ''4'': Value of Exports Calculated on F.O.B. basis*: Rs. 43,97,69,065 (Based on shipping Bills) (Rs. 27,48,53,304)

* Excluding Domestic Sales for Export

NOTE ''5'': Expenditure in Foreign Currency: Rs. 40,59,573.40

(Rs. 39,77,367.00)

NOTE ''6'': The outstanding balances as on 31st March, 2017 in respect of parties are subject to verification.

NOTE ''7'': The Company has one segment of activity namely "Pharmaceuticals".

NOTE ''8'': Misc. Expenditure includes Rs. 56,562/- as contribution of medicines for Social Welfare to Charitable Institution.

NOTE ''9'': Total pending allotment of Equity shares are 551694 on conversion of warrants as on 31st March, 2017 on account of Money received against share warrants.

NOTE ''10'': The Company is partner in Panache Life care LLP having 33.33332% share but during the year there is no any transaction made in Panache Life care LLP Therefore share of Profit & loss is also NIL on the basis of provisional Financial Statements as on 31st March, 2017 and the difference if any shall be adjusted in the books on the finalization of said Financial statements.

NOTE ''11'': In view of the requirements of Schedule II of the Companies Act 2013 ("Act"), depreciation for the year has been provided based on the lives prescribed under the schedule II.

NOTE ''12'': The Company has during the year paid total managerial remuneration within limit under Section 197 read with schedule V of the Companies Act, 2013 of Rs.15,74,428/- (excluding retirement benefits of Rs. 26,00,000/-)

NOTE ''13'': Related party disclosure as required by AS-18: Related Party Disclosures'' notified by the Companies

(Accounting Standard) Rules, 2006 are given below: Name and Relationships of the Related Parties:

(i) Associate Concern

(a) Medicamen Organics Limited

(b) Panache Lifecare LLP.

(c) Shivalik Rasayan Limited

(d) Growel Capital Services Private Limited

(e) Ms. Kanchan Sharma

(ii) Key Management Personnel

(a) Mr. Rahul Bishnoi - Chairman

(b) Mr. Suresh Kumar Singh - Director

(c) Mr. Ashwani Kumar Sharma - Director

(d) Mr. Klaus Snej Jensen - Director

(e) Mr. Harish Pande - Director

(f) Ms. Usha Pande - Director

(g) Mr. Sanjay Bansal - Director

(h) Mr. Arun Kumar - Director

(i) Mr. Ashutosh Gupta - Director

(j) Mr. Ashok Babu Jha - Whole Time Director (k) Mr. Rajesh Madan Chief Executive Officer (l) Mr. Himanshu Bansal - Chief Financial Officer (m) Ms. Kiran - Company Secretary Transactions with the related parties during the year:

NOTE ''14'': Previous Year''s figures have been regrouped or recast wherever considered necessary.

---

Mar 31, 2016

NOTE ''1'':

Information required to be disclosed under Micro, Small and Medium Enterprises Development Act, 2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as per terms except for special reasons.

NOTE 2'':

Contingent Liabilities: In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

NOTE ''3'':

The outstanding balances as on March 31, 2016 in respect of parties are subject to verification.

NOTE 4'': the assets, therefore no provision for impairment in value thereof has been considered necessary, by the management.

The Company has one segment of activity namely “Pharmaceuticals”.

NOTE ''5'':

Misc. Expenditure includes Rs.68,268/- as contribution of medicines for Social Welfare to Charitable Institution. NOTE 35'':

There is no pending allotment of shares on conversion of warrants as on 31st March 2016 on account of Money received against share warrants.

NOTE 6'':

The Company is partner in Panache Lifecare LLP having 33.33332% share but during the year there is no any transaction made in Panache Lifecare LLP Therefore share of Profit & loss is also NIL on the basis of provisional Financial Statements as on 31.03.2016 and the difference if any shall be adjusted in the books on the finalization of said Financial statements.

NOTE 7'':

In view of the requirements of Schedule II of the Companies Act 2013 (“Act”), depreciation for the year has been provided based on the lives prescribed under the schedule II.

NOTE 8'':

The Company has during the year paid total managerial remuneration of Rs.82,40,518/- (excluding retirement benefits of Rs.5,72,400/-). Pursuant to Section 197 read with schedule V of the Companies Act, 2013 the Company can pay maximum Rs.84,00,000/- as managerial remuneration.

NOTE 9'':

Related party disclosure as required by AS-18: Related Party Disclosures’ notified by the Companies (Accounting Standard) Rules, 2006 are given below :

Name and Relationships of the Related Parties:

(i) Associate Concern

(a) Medicamen Organics Ltd.

(b) Red Line Healthcare.

(c) Panache Lifecare LLP.

(d) Shivalik Rasayan Ltd.

(ii) Key Management Personnel

(a) Mr. B.K. Gupta - Managing Director

(b) Mr. Ashutosh Gupta - Director

(c) Mr. Jitendra Nath Ojha - Whole Time Director

(d) Mr.Rahul Bishnoi - Chairman

(e) Mr. Ashok Babu Jha - Whole Time Director

(f) Mr.Ashwani Kumar Sharma - Director

(g) Mr.Harish Pande - Director

(h) Mr.Suresh Kumar Singh - Director

(i) Mrs.Usha Pande - Director (j) Mr.Sanjay Bansal - Director (k) Mr.Arun Kumar - Director

(l) Mr. Rajesh Kumar Gupta - Chief Financial Officer

(m) Ms. Kiran - Company Secretary

NOTE 10'':

Previous Year’s figures have been regrouped or recast wherever considered necessary.

---

Mar 31, 2015

NOTE 1:

Information required to be disclosed under Micro, Small and Medium Enterprises Development Act, 2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as per terms except for special reasons.

NOTE 2:

Contingent Liabilities: In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

NOTE 3:

The outstanding balances as on March 31, 2015 in respect of parties are subject to verification.

NOTE 4:

The Company has one segment of activity namely "Pharmaceuticals".

NOTE 5:

Misc. Expenditure includes Rs.4,99,378/- as contribution of medicines for Social Welfare to Charitable Institution.

NOTE 6:

Money received against share warrants includes Rs. 15,45,555/- on account of pending allotment of shares on conversion of warrants.

NOTE 7:

The Company is partner in Panache Lifecare LLP having 33.33332% share and share of loss of Rs.3,06,800.41 has been provided for in the books on the basis of provisional Financial Statements as on 31.03.2015 and the difference if any shall be adjusted in the books on the finalization of said Financial statements.

NOTE 8:

In view of the requirements of Schedule II of the Companies Act 2013 ("Act"), depreciation for the year has been provided based on the lives prescribed under the schedule II. Further in view of transitional provision of the Schedule II, a sum of Rs. 47,82,693.02 has been recognized in the opening balance of the retained earnings of those assets whose useful life was nil as on 31st March 2014 as per the provision of Schedule II.

NOTE 9:

The Company has during the year paid total managerial remuneration of Rs.94,14,022/- (excluding retirement benefits of Rs.6,76,800 and commission of Rs. 24,186/-). Pursuant to Section 197 read with schedule V of the Companies Act, 2013 the Company can pay maximum Rs.84,00,000/- as managerial remuneration. However as per the agreement for managerial remuneration with the managing Director dated 13.08.2013 he is entitled for the amount paid but in view of the provisions of Section 197 and schedule V the approval of Central Government is required which is pending disposal. In case it is not approved the excess amount shall be recovered from the managing Director and shown accordingly in the books of accounts.

NOTE 10:

Related party disclosure as required byAS-18: Related Party Disclosures' notified by the Companies (Accounting Standard) Rules, 2006 are given below :

Name and Relationships of the Related Parties:

(i) Associate Concern

(a) Medicamen Organics Ltd.

(b) Red Line Healthcare.

(c) Panache Lifecare LLP.

(ii) Key Management Personnel

(a) Mr. B.K. Gupta - Managing Director

(b) Mr. Ashutosh Gupta - Whole Time Director

(c) Mr. Jitendra Nath Ojha - Whole Time Director

(d) Mr. Rajesh Kumar Gupta - Chief Financial Officer

(e) Ms. Kiran - Company Secretary

NOTE 11:

Previous Year's figures have been regrouped or recast wherever considered necessary.

---

Mar 31, 2014

NOTE ''1'':

Information required to be disclosed under Micro, Small and Medium Enterprises Development Act, 2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as pertermsexceptforspecial reasons.

NOTE 2:

Contingent Liabilities: In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

NOTE 3:

The outstanding balances as on March 31,2014 in respect of parties are subject to verification.

NOTE ''4'':

The Company has one segment of activity namely "Pharmaceuticals".

NOTE ''5'':

Misc. Expenditure includes Rs.8,33,212/- as contribution of medicines for Social Welfare to Charitable Institution.

NOTE ''6'':

Related partydisclosure as required byAS-18: Related Party Disclosures'' notified bythe Companies (Accounting Standard) Rules, 2006 are given below :

Name and Relationships ofthe Related Parties:

(i) Associate Concern

(a) Medicamen Organics Ltd.

(b) Red Line Healthcare.

(ii) Key Management Personnel

(a) Mr. B.K. Gupta

(b) Mr. Ashutosh Gupta

(c) Mr. Jitendra Nath Ojha

Transactions with the related parties during the year:

NOTE ''7'':

Previous Year''s figures have been regrouped or recast wherever considered necessary.

---

Mar 31, 2013

NOTE 1 :

Information required to be disclosed under Micro, Small and Medium Enterprises Development Act, 2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as per terms except for special reasons.

NOTE 2 :

Contingent Liabilities: In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

NOTE 3 :

Value of Imports Calculated on C.I.F. basis: Rs.3,07,17,728

(Rs.4,36,34,228)

NOTE 4 :

Value of Exports Calculated on F.O.B. basis*: Rs.22,42,42,916

(Based on shipping Bills) (Rs. 59,55,19,483)

* Excluding Domestic Sales for Export

NOTE 5 :

Expenditure in Foreign Currency: Rs.14,28,041

(Rs.11,14,270)

NOTE 6 :

The outstanding balances as on March 31, 2013 in respect of parties are subject to verification.

NOTE 7 :

The Company has one segment of activity namely "Pharmaceuticals".

NOTE 8 :

Misc. Expenditure includes Rs.10,22,568/- as contribution of medicines for Social Welfare to Charitable Institution.

NOTE 9 :

Related party disclosure as required by AS-18: Related Party Disclosures'' notified by the Companies (Accounting Standard) Rules, 2006 are given below :

Name and Relationships of the Related Parties:

(i) Associate Concern

(a) Medicamen Organics Ltd.

(b) Red Line Healthcare.

(ii) Key Management Personnel

(a) Sh. B. K. Gupta

(b) Sh. Ashutosh Gupta

(c) Mr. Piyush Gupta

(d) Mr. J.P. Nirula

(e) Mr. Anand Kumar Mishra

NOTE 10 :

Previous Year''s figures have been regrouped or recast wherever considered necessary.

---

Mar 31, 2012

NOTE `1`:

Information required to be disclosed under Micro, Small and Medium Enterprises Development Act, 2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as per terms except for special reasons.

NOTE `2`:

Contingent Liabilities: In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

NOTE `3`:

The outstanding balances as on March 31, 2012 in respect of parties are subject to verification.

NOTE `4`:

The Company has one segment of activity namely "Pharmaceuticals".

NOTE `5`:

Misc. Expenditure includes Rs.9,98,244/- as contribution of medicines for Social Welfare to Charitable Institution.

NOTE `6`:

The Amount of Rs. 25,30,050.00 received as capital subsidy from Govt. against purchase of machinery shown as capital reserve is transferred to respective assets.

NOTE `7`:

Related party disclosure as required by AS-18: Related Party Disclosures' notified by the Companies (Accounting Standard) Rules, 2006 are given below :

Name and Relationships of the Related Parties:

(i) Associate Concern

(a) Medicamen Organics Ltd.

(b) Red Line Healthcare.

(ii) Companies in which Director is Director

(a) Mission Pharma Logistics (India) Pvt. Ltd.

(b) Mission Pharma A/S

(iii) Key Management Personnel

(a) Mr. B.K. Gupta

(b) Mr. Ashutosh Gupta

(c) Mr. Piyush Gupta

NOTE `8`:

The Financial Statements for the year ended 31st March 2011 had been prepared as per the then applicable, pre-revised Schedule VI to the Companies Act, 1956. Consequent to the notification of Revised Schedule VI under the Companies Act, 1956, The Financial Statement for the year ended 31st March 2012 are prepared as per Revised Schedule VI. Accordingly the previous year figures have also been reclassified to conform to this year classification. The adoption of Revised Schedule VI for previous year figure does not impact recognition and measurement principal followed for preparation of Financial Statements.

---

Mar 31, 2011

1. a) Bank Guarantee given by the bankers on behalf of the Company is Rs. 345.64 Lacs as on the date of balance sheet (Previous year Rs. 484.14 lacs)

b) Letter of Credit issued by the Bankers of the Company and outstanding against Material Rs. 999.72 lacs (PreviousyearRs.614.12 lacs)

2. In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realisation In the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

3. Previous Year's figures have been regrouped or recast wherever considered necessary.

4. Capital Work in Progress : It includes advances to suppliers of building materials, plant & machineries and other capital assets & will be allocated to fixed assets in year in which such assets will be ready for utilisation

5. The outstanding balances as on March 31,2011 in respect of parties are subject to verification.

6. The cost of lease land alongwith development expenditure thereon has been amortised over the lease life of the land. During the year the company has written off Rs. 76009 for Bhiwadi and Rs.21098 for Hardwar Land.

7. The closing stock as on 31st March, 2011 is as taken, valued and certified by the management.

- Raw Material,Packing Material and Finished Goods are valued at cost or net realisable value whichever is lower

- Work in Progress are valued at estimated cost

- Stores and spares are valued at cost. Closing stock of finished goods does not include excise duty.

8. Rs. 109,04,390/- shown as Fixed Deposit Receipt with banks is including interest accrued and is lying as security with the parties/Govt. Departments or margin money with bank.

9. Travelling includes directors'travelling of Rs. 22,03,688/- (Previous year 15,00,771 /-)

10. The Company has provided Employees Benefits as per the Accounting Standard-15 issued by the Institute of Chartered Accountants of India. Provision for Gratuity and Leave Encashment have been made in the books of accounts on the basis of actuarial valuation using the Project Unit Credit Method.

11. Company has made provision for deferred tax effect on the difference of depreciation between the amount, as per Income Tax rules and profit & loss account for the year and accumulated retirement benefit provided for during the year.

12. The Company has one segment of activity namely "Pharmaceuitcals".

13. Misc. Expenditure includes Rs. 16,92,712 as contribution of medicines for Social Welfare to Charitable Institution.

14. In terms of requirements of the Accounting Standards-28 on "Impairment of Assets" issued by the Institute of Chartered Accountants of India, the amount recoverable against Fixed Assets has been estimated for the period end by the management based on their present value of estimated future cash flows expected to arise from the continuing use of such assets. The recoverable amount so assessed was found to be adequate to cover the carrying amount of the assets, therefore no provision for impairment in value therof has been considered neccesary, by the management.

15. Information required to be disclosed under Micro,Small and Medium Enterprises Development Act,2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as per terms except for special reason.

16. A sum of Rs.25,30,050 received as Capital subsidy against project at Haridwar is shown as Capital Reserve.

17. Related Party Disclosure

Related party disclosure as required by AS-18 , Related Party Disclosures' notified by the Companies (Accounting Standard) Rules, 2006 are given below : Name and Relationships of the Related Parties :

(i) Associate Concern

(a) Medicamen Organics Ltd. (b) Red Line Healthcare

(ii) Companies in which Director is Director

(a) Mission Pharma Logistics (India) Pvt. Ltd. (b) Mission Pharma A/S

(iii) Key Management Personnel

(a) Mr.B.K.Gupta

(b) Mr.Ashutosh Gupta

(c) Mr.Piyush Guptaf

---

Mar 31, 2010

1. a) Inland and Foreign Guarantee given by the bankers on behalf of the Company is Rs.484.14 Lacs as on the date of balance sheet (Previous year Rs.308.65 lacs )

b) Letter of Credit issued by the Bankers of the Company and outstanding against Raw Material Rs.614.12 lacs (Previous year Rs.267.27 lacs)

2. In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities.The value of current assets, loans and advances have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

3. Previous Years figures have been regrouped or recast wherever considered necessary.

4. Capital Work in Progress : It includes advances to suppliers of building materials, plant & machineries and other capital assets & will be allocated to fixed assets in year in which such assets will be ready for utilisation

5. The outstanding balances as on March 31, 2010 in respect of parties are subject to verification.

6. The cost of lease land alongwith development expenditure thereon has been amortised over the lease life of the land. During the year the company has written off Rs. 76009 for Bhiwadi and Rs.21098 for Hardwar Land.

7. The closing stock as on 31 st March, 2010 is as taken, valued and certified by the management.

- Raw Material,Packing Material and Finished Goods are valued at cost or net realisable value whichever is lower

- Work in Progress are valued at estimated cost

- stores and spares are valued at cost. Closing stock of finished goods does not include excise duty.

9. Rs.93,10,279/- shown as Fixed Deposit Receipt with banks is including interest accrued and is lying as security with the parties/Govt. Departments or margin money with bank.

10. Travelling includes directors travelling of Rs. 15,00,771/- (Previous year 7,30,327/-)

11. The Company has provided Employees Benefits as per the Accounting Standard-15 issued by the Institute of Chartered Accountants of India. Provision for Gratuity and Leave Encashment have been made in the books of accounts on the basis of actuarial valuation using the Project Unit Credit Method.

12. Company has made provision for deferred tax effect on the difference of depreciation between the amount, as per Income Tax rules and profit & loss account for the year and accumulated retirement benefit provided for during the year.

13. The Company has one segment of activity namely "Pharmaceuitcals".

14. Misc. Expenditure includes Rs.26,38,252.00 as contribution of medicines for Social Welfare to Charitable Institution.

15. Remuneration of Rs.44,43,477.00 provided for Managing Director is subject to approval of Government which is still awaited.

16. Earning Per Share (EPS) - The numerator and denominator used to calculate Basic and Diluted Earnings per Share:

17. In terms of requirements of the Accounting Standards-28 on "Impairment of Assets" issued by the Institute of Chartered Accountants of India, the amount recoverable against Fixed Assets has been estimated for the period end by the management based on their present value of estimated future cash flows expected to arise from the continuing use of such assets.The recoverable amount so assessed was - found to be adequate to cover the carrying amount of the assets, therefore no provision for impairment in value there of has been considered neccesary, by the management.

18. Information required to be disclosed under Micro, Small and Medium Enterprises Development Act,2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as per terms except for special reason.

19. Related Party Disclosure

Related party disclosure as required by AS-18 , Related Party Disclosures notified by the Companies (Accounting Standard) Rules, 2006 are given below : Name and Relationships of the Related Parties :

(i) Associate Concern

(a) Medicamen Organics Ltd.

(b) Red Line Healthcare

(ii) Companies in which Director is Director / CEO

(a) Mission Pharma Logistics (India) Pvt. Ltd.

(b) Mission Pharma A/S

(iii) Key Management Personnel

(a) Mr.B.K.Gupta

(b) Mr.Ashutosh Gupta